almorexant: Clinical Trials

6 trials of almorexant, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed. 3 Phase 1, 1 Not applicable, 1 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 13Completed 3
Not applicable1Completed 1
Phase 21Completed 1
Phase 31Completed 1

Follow almorexant: new trials by email Literature Review of almorexant trials Research Report on almorexant

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-462206
ACT-462206 5 mg, ACT-462206 25 mg, ACT-462206 100mg - Safety, Tolerability
Phase 1CompletedIdorsia Pharmaceuticals Ltd.562011-11-012018-07-10
Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance
Almorexant, Zolpidem 10mg, Placebo - Healthy Volunteers
Not applicableCompletedNorthern California Institute of Research and Education2032011-05-012014-10-06
Study to Evaluate the Relative Abuse Potential of Almorexant in Recreational Drug Users
200 mg almorexant, 400 mg almorexant, 1000 mg almorexant - Abuse Potential Study
Phase 1CompletedMidnight Pharma, LLC422009-09-012016-02-12
Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia
almorexant, Placebo, zolpidem - Primary Insomnia
Phase 3CompletedMidnight Pharma, LLC7092008-03-012016-03-14
Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia
ACT-078573 oral capsules at 25 and 100 mg and matching placebo, ACT-078573 and matching placebo - Chronic Primary Insomnia
Phase 2CompletedMidnight Pharma, LLC1122007-12-012016-03-14
Almorexant in Primary Insomnia
almorexant - Insomnia, Primary Insomnia
Phase 1CompletedMidnight Pharma, LLC1612006-05-012016-02-12

Conditions studied

Sleep Initiation and Maintenance Disorders (3)

Sponsors

Midnight Pharma, LLC (4)  ·  Idorsia Pharmaceuticals Ltd. (1)  ·  Northern California Institute of Research and Education (1)

Countries

Austria (2)  ·  Denmark (2)  ·  Finland (2)  ·  Germany (2)  ·  Israel (2)  ·  Netherlands (2)  ·  Spain (2)  ·  Sweden (2)  ·  Switzerland (2)  ·  United Kingdom (2)  ·  United States (2)  ·  Australia (1)  ·  Belgium (1)  ·  Bulgaria (1)  ·  Czechia (1)

Top investigators

Edward M Sellers, MD, PhD (1)  ·  Eleornora Chiossi, MSc (1)  ·  Fabrice Kramer, MD (1)  ·  Georg Dorffner, Prof. Dr. (1)  ·  James K. Walsh, PhD (1)  ·  Jasper Dingemanse, PhD (1)  ·  Petra Baecker, MD (1)  ·  Petra Hoever, MSc (1)  ·  Raymond Cluydts, Dr. (1)  ·  Thomas Neylan, M.D. (1)

Results publications

PMID 22549286, PMID 28735928